Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionVan Eck Associates Corp
Latest Disclosed Ownership54,137 shares
Latest Disclosed Value $ 17,912
Van Eck Associates Corp reports 12.97% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Van Eck Associates Corp filed a 13F-HR form disclosing ownership of 54,137 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $15,466,941 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 47,922 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 12.97% during the quarter. The current value of the position is $13,631,697 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 54,137 6,215 12.97 18 -10.53 0.0117
2026-02-13 2025-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 47,922 6,789 16.50 19 5.56 0.0157
2025-11-13 2025-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 41,133 -13,427 -24.61 19 5.88 0.0174
2025-08-14 2025-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 54,560 -9,584 -14.94 18 0.00 0.0201
2025-05-15 2025-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 64,144 -3,674 -5.42 17 13.33 0.0224
2025-01-29 2024-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 67,818 10,419 18.15 16 -6.25 0.0204
2024-10-29 2024-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 57,399 -3,539 -5.81 17 14.29 0.0211
2024-07-31 2024-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 60,938 3,015 5.21 15 75.00 0.0210
2024-04-30 2024-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 57,923 -3,310 -5.41 9 -27.27 0.0131
2024-02-05 2023-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 61,233 -9,853 -13.86 12 -8.33 0.0213
2023-11-08 2023-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 71,086 -6,882 -8.83 13 -14.29 0.0276
2023-08-03 2023-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 77,968 -3,313 -4.08 15 -12.50 0.0324
2023-05-03 2023-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 81,281 -11,099 -12.01 16 -23.81 0.0371
2023-02-08 2022-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 92,380 22,484 32.17 22 -99.85 0.0567
2022-10-27 2022-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 69,896 -39,546 -36.13 13,991 -12.35 0.0416
2022-08-03 2022-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 109,442 9,436 9.44 15,962 -2.25 0.0423
2022-05-10 2022-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 100,006 1,392 1.41 16,330 -2.35 0.0337
2022-01-26 2021-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 98,614 5,913 6.38 16,723 -4.46 0.0387
2021-11-03 2021-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 92,701 -27,921 -23.15 17,503 -14.40 0.0440
2021-08-10 2021-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 120,622 20,368 20.32 20,448 44.46 0.0484
2021-05-13 2021-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 100,254 -4,975 -4.73 14,155 3.49 0.0385
2021-02-09 2020-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 105,229 18,790 21.74 13,677 8.67 0.0398
2020-12-04 2020-09-30 13F/A-1 Alnylam Pharmaceuticals COM 02043Q107 86,439 -24,559 -22.13 12,586 -23.44 0.0401
2020-11-12 2020-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 86,439 -24,559 12,586 39,021.0546
2020-08-14 2020-06-30 13F/A-1 Alnylam Pharmaceuticals COM 02043Q107 110,998 23,994 27.58 16,440 73.60 0.0573
2020-08-10 2020-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 110,998 23,994 16,440 55,850.8126
2020-05-12 2020-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 87,004 -27,922 -24.30 9,470 -28.45 0.0481
2020-02-13 2019-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 114,926 3,885 3.50 13,236 48.22 0.0511
2019-11-08 2019-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 111,041 6,592 6.31 8,930 17.83 0.0418
2019-08-07 2019-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 104,449 -20,824 -16.62 7,579 -35.26 0.0365
2019-05-13 2019-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 125,273 9,228 7.95 11,707 38.36 0.0575
2019-02-12 2018-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 116,045 4,622 4.15 8,461 -13.24 0.0424
2018-11-13 2018-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 111,423 33,228 42.49 9,752 26.63 0.0476
2018-08-13 2018-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 78,195 10,950 16.28 7,701 -3.85 0.0360
2018-05-11 2018-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 67,245 -19,454 -22.44 8,009 -27.29 0.0398
2018-02-12 2017-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 86,699 -68,486 -44.13 11,015 -39.59 0.0543
2017-11-09 2017-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 155,185 27,135 21.19 18,233 78.53 0.0931
2017-08-11 2017-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 128,050 25,273 24.59 10,213 93.91 0.0558
2017-05-11 2017-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 102,777 -23,915 -18.88 5,267 11.05 0.0232
2017-02-09 2016-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 126,692 -2,179 -1.69 4,743 -45.70 0.0236
2016-11-14 2016-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 128,871 -26,252 -16.92 8,735 1.48 0.0407
2016-08-12 2016-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 155,123 -16,756 -9.75 8,608 -20.22 0.0441
2016-05-13 2016-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 171,879 -21,991 -11.34 10,789 -40.89 0.0727
2016-02-12 2015-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 193,870 43,021 28.52 18,251 50.56 0.1448
2015-11-12 2015-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 150,849 -55,133 -26.77 12,122 -50.91 0.0931
2015-08-12 2015-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 205,982 18,554 9.90 24,691 26.16 0.1460
2015-05-14 2015-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 187,428 187,428 19,571 0.1130
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.